Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-sensitive Recurrent Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01133756
What this trial is testing

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Who this might be right for
Ovarian Cancer
Eisai Inc. 7
Testing effectiveness (Phase 2)Study completedNCT01767675
What this trial is testing

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tubes CancerPeritoneal Cancer
Memorial Sloan Kettering Cancer Center 99
Not applicableStudy completedNCT03562533
What this trial is testing

Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Carcinoma
Konkuk University Medical Center 432
Testing effectiveness (Phase 2)Looking for participantsNCT03983226
What this trial is testing

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Who this might be right for
Ovarian Cancer RecurrentFallopian Tube CancerPrimary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group 167
Not applicableStudy completedNCT04573933
What this trial is testing

Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.

Who this might be right for
Ovarian Neoplasm
University Hospital, Brest 54
Large-scale testing (Phase 3)Looking for participantsNCT07225270
What this trial is testing

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Who this might be right for
Ovarian CancerPlatinum-sensitive Ovarian CancerPSOC
Genmab 544
Not applicableStudy completedNCT03505307
What this trial is testing

Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)

Who this might be right for
Ovarian Cancer
AstraZeneca 846
Testing effectiveness (Phase 2)Study completedNCT03759587
What this trial is testing

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Takeda 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT04550494
What this trial is testing

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate Carcinoma+28 more
National Cancer Institute (NCI) 29
Early research (Phase 1)UnknownNCT01387399
What this trial is testing

Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
University Hospital, Bonn 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT04938583
What this trial is testing

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer by FIGO StageOvarian Cancer Stage IIIOvarian Cancer Stage IV
CanariaBio Inc. 54
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07776171
What this trial is testing

Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian CancerPlatinum Sensitive Ovarian Cancer (PSOC)
Sun Yat-sen University 176
Testing effectiveness (Phase 2)Study completedNCT00267696
What this trial is testing

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Ohio State University Comprehensive Cancer Center 45
Testing effectiveness (Phase 2)Study completedNCT01188876
What this trial is testing

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Massachusetts General Hospital 50
Early research (Phase 1)Looking for participantsNCT05942300
What this trial is testing

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian Cancer
Lan Coffman 30
Large-scale testing (Phase 3)UnknownNCT01802749
What this trial is testing

Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

Who this might be right for
Recurrent Ovarian Cancer
National Cancer Institute, Naples 406
Testing effectiveness (Phase 2)Study completedNCT01690598
What this trial is testing

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Who this might be right for
Ovarian Cancer
Vejle Hospital 22
Testing effectiveness (Phase 2)Study completedNCT01033123
What this trial is testing

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Sanofi 41
Testing effectiveness (Phase 2)Study completedNCT02759588
What this trial is testing

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CarcinomatosisFallopian Tube Cancer
Genelux Corporation 46
Large-scale testing (Phase 3)WithdrawnNCT03905902
What this trial is testing

DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Carcinoma
SOTIO a.s.
Next Page